Selection of individual experts for joint scientific consultations
Article 5
1. When selecting the medicinal products that are to be subject to joint scientific consultations, the JSC Subgroup shall specify, for each medicinal product, the following: (a) the disease; (b) the therapeutic area; (c) other specific expertise if needed for the joint scientific consultation. 2. On the basis of the information listed in paragraph 1, the HTA secretariat shall identify individual experts to be consulted during the joint scientific consultation and shall compile a list of relevant individual experts, in consultation with the JSC Subgroup and the assessor and co-assessor for joint scientific consultation appointed pursuant to Article 18(3) of Regulation (EU) 2021/2282 (‘the assessor and co-assessor’). When compiling the list, the HTA secretariat may consult one or more of the following: (a) the members of the stakeholder network established pursuant to Article 29 of Regulation (EU) 2021/2282; (b) the European reference networks for rare and complex diseases and their respective European patient advocacy groups; (c) the portal for rare diseases and orphan drugs; (d) the national contact points designated in accordance with Article 83(1) of Regulation (EU) No 536/2014 of the European Parliament and of the Council ( 6 ) ; (e) the European Medicines Agency. 3. Where the consultation of the sources referred to in paragraph 2 has not yielded a sufficient number of relevant individual experts, the HTA secretariat may consult the following for compiling a list of individual experts: (a) other databases or directories than the ones listed in paragraph 2; (b) members of the Coordination Group and its subgroups; (c) relevant Union and international agencies and organisations. 4. After the Commission, in accordance with the rules set out in Article 5 of Regulation (EU) 2021/2282 and Article 4 of Implementing Regulation (EU) 2024/2745, has assessed the declared interests of individual experts in the list compiled by the HTA secretariat in accordance with paragraphs 1 to 3 of this Article, the HTA secretariat shall provide the JSC Subgroup with a list of available individual experts. 5. The JSC Subgroup shall make the final selection of individual experts to be consulted during the joint scientific consultation from the list of individual experts provided by the HTA Secretariat in accordance with paragraph 4. In making the final selection, the JSC Subgroup shall give priority to individual experts who have expertise across a number of Member States in the disease or the therapeutic area of the joint scientific consultation.